Nuvalent completes $10.6 billion merger with GlaxoSmithKline subsidiary, becomes wholly owned subsidiary with new leadership and Nasdaq delisting requested

Key Facts

Mergers and acquisitions

• Status: On July 15, 2026, Purchaser merged with and into Nuvalent, Inc.; Nuvalent survived as a direct wholly owned subsidiary of Parent.
• Transaction value and consequence: The transaction resulted in a change in control, with approximately $10.6 billion of total equity value.
• Financing: Parent funded the Merger and related transactions with borrowings under its credit facilities.
• Condition and approval: The Merger was completed under Sections 251(c) and 251(h) of the DGCL without a stockholder vote.

Leadership and compensation

• James R. Porter, Ph. D., Grant C. Bogle, Michael L. Meyers, M.D., Ph. D., Christy Oliger, Anna Protopapas, Ron Squarer, Sapna Srivastava, Ph. D., and Cameron A. Wheeler, Ph. D. resigned from their respective positions as members of the Company’s board of directors and any committee thereof at the Effective Time.
• Justin T. Huang and Kevin T. Ryan became directors of the Company as the surviving corporation at the Effective Time.
• Each incumbent officer of the Company ceased to be an officer at the Effective Time.
• At the Effective Time, Justin T. Huang became President and Secretary, Kevin T. Ryan became Vice President and Treasurer, and Hatixhe Hoxha became Assistant Secretary of the Company as the surviving corporation.

Governance and shareholder rights

• Adopted board change: all incumbent directors resigned from the board and its committees at the Effective Time.
• Adopted board change: Justin T. Huang and Kevin T. Ryan became directors of the surviving corporation.
• Shareholder-rights effect: former holders of Shares ceased to have stockholder rights at the Effective Time, except for the right to receive the Offer Price.

Listing and exchange compliance

• Nuvalent notified Nasdaq of the Merger consummation.
• The Company requested a Nasdaq trading halt after market close on July 14, 2026 and suspension before market open on July 15, 2026.
• The Company requested that Nasdaq file Form 25 to effect delisting of all Shares from Nasdaq.
• The requested delisting included deregistration under Section 12(b) of the Exchange Act.
• The Company intended to file Form 15 requesting suspension of its Exchange Act reporting obligations.

Source

View the source SEC filing